Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation
3 Months Ended
Mar. 31, 2018
Share-based compensation  
Share-based compensation


Note 10 — Share-based compensation


The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (thousands):




Three months ended
March 31,








Research and development








General and administrative





























There were 9,994,656 and 18,950,976 options over ordinary shares granted in the three months ended March 31, 2018 and 2017, respectively, with a weighted average fair value of $0.75 and $0.34, respectively. Additionally, in the three months ended March 31, 2018, 6,552,636 options were granted, which have a nominal exercise price (similar to a restricted stock unit (RSU)).  These options had a weighted average fair value of $1.34.


The RSU-style options over ordinary shares in Adaptimmune Therapeutics plc were granted under the Adaptimmune Therapeutics plc Employee Share Option Scheme (adopted on January 14, 2016).  These options have an exercise price equal to the nominal value of an ordinary share, of £0.001, and generally vest over four years, with 25% on the first, and each subsequent, anniversary of the grant date.  The RSU-style options are not subject to performance conditions and the contractual term is ten years.